News
-
-
PRESS RELEASE
BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF
BioNxt Solutions reports successful comparative pharmacokinetics study in pigs for sublingual cladribine ODF formulation, showing superior bioavailability and potential benefits for Multiple Sclerosis therapy. Internal analysis ongoing -
-
PRESS RELEASE
Over 40% of Adults Struggle to Swallow Pills - BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies
BioNxt Solutions Inc. announces breakthrough in drug delivery for dysphagia, securing first national-level patent for thin-film platform, targeting autoimmune markets with bioequivalent cladribine treatment -
-
PRESS RELEASE
BioNxt Advances "Melt in Your Mouth" Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia
BioNxt Solutions Inc. is developing a sublingual cladribine ODF to enhance MS treatment access. The innovative technology aims to improve swallowing difficulties and increase therapy adherence -
-
PRESS RELEASE
BioNxt Signs Letter Agreement to Acquire 100% Interest in IP and to Codevelop a Sublingual Drug Formulation for Chemotherapy and Immunosuppressant Treatments
BioNxt Solutions collaborates with European chemotherapy company for novel sublingual drug formulation with high-potency ingredient. Focus on oncology and immunosuppressant treatments. Company plans to expand IP portfolio -
-
PRESS RELEASE
BioNxt Secures Final Patent Grant from the Eurasian Patent Organization for Sublingual Cladribine Platform
BioNxt Solutions Inc. receives Eurasian Patent No. 051510 for sublingual anticancer drug delivery system, a key milestone in global IP strategy. Expansion to EU and US markets in progress
